Payers and health technology assessment bodies in the Netherlands, Germany and Italy are either unwilling to use real-world data in assessments or cannot due to their existing frameworks, say representatives from Gilead Sciences and Autolus Therapeutics.
Dilip Patel, Nneka Onwudiwe, Angela Borghouts-de Ruijter, Paolo Morgese and Matias Olsen at the Advanced Therapies Congress in London, 2025 (Norstella)
Key Takeaways
The Dutch health technology assessment agency is willing to use real-world data in appraisals this is difficult under the current framework, an executive from Gilead says.
Real-world data (RWD) and real-world evidence (RWE) have the potential to help support companies in demonstrating the value of novel...
